ISMPP and Open Science – a perspective from Oxford PharmaGenesis
Champion sponsor of the Annual Meeting
Written by Chris Winchester, CEO, Oxford PharmaGenesis
This year’s virtual Annual Meeting of ISMPP marked the end of my 3 years on the Board of Trustees, and a chance to reflect on our achievements in that time. As well as managing the transition from one extremely talented President and CEO (Al Weigel) to another (Rob Matheis), we agreed a new mission and vision broadening our remit beyond publications to medical communications, and I was pleased to see that reflected strongly in the meeting program.
As a co-founder of Open Pharma, I was keen to use my time on the Board to advance Open Science, and so was proud that ISMPP made Open Access the subject of its first White Paper last year.
Of course, Open Access and preprints have played an important role in accelerating the scientific response to COVID-19, and I commend the program committee for making Open Science in general, and Open Access in particular, key themes of this year’s conference in the time of coronavirus.